🕒 Wednesday 18 February 2026 Wed, 18 Feb 2026

Spheria Emerging Companies Limited has reported a solid 16.8% increase in profit after tax for the half-year ending December 2025, alongside a strategic shift introducing monthly fully franked dividends.

MEC Resources Ltd reported a half-year loss of $431,971 amid ongoing legal challenges over key gas exploration permits, while progressing investments in clean energy and neurotechnology. The company also completed a $359K options placement, reinforcing its financial position.

Infragreen Group Limited reports a remarkable turnaround with a statutory net profit of A$3.64 million for H1 2025 and declares its inaugural interim dividend, underscoring confidence in its sustainable infrastructure investments.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Glennon Small Companies Limited reported a half-year loss for the period ending 31 December 2025, driven by significant investment portfolio losses. Despite this, the company declared dividends and extended a key convertible loan.

InvestSMART Group Ltd reports a solid half-year performance with funds under management reaching $750 million and a growing subscriber base, while outlining plans to enhance its digital wealth platform with AI and new services.

Global X Management (AUS) Limited has announced estimated distributions for three ETFs listed on the ASX AQUA Market for the period ending 28 February 2026, providing key dates and dividend reinvestment plan eligibility.

Austco Healthcare has reported a robust first half of 2026, with revenue surging 31% and EBITDA jumping 60%, underpinned by solid contract backlog and debt-free balance sheet.

IGNITE Limited reports a challenging first half of FY26 with an 18% revenue decline and a halving of statutory profit, yet maintains a fully franked interim dividend amid a strategic business closure.

Alcoa of Australia has partnered with the federal government to overhaul the environmental approvals process for its Western Australian mining operations, committing $55 million to conservation efforts and securing operational certainty through 2045.

AuMEGA Metals has successfully upsized its institutional financing to C$30.1 million, anchored by Condire Investors who will hold nearly 20% of the company. The funds will accelerate exploration programs across its Newfoundland gold projects.

Bell Financial Group delivered a robust 17.1% rise in net profit after tax to $36 million for 2025, driven by strong growth in its Platforms division and a rebound in market activity. The company declared a fully franked final dividend of 6.5 cents per share, signalling confidence as it prepares to launch a new wealth management platform in 2026.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Kaili Resources has reported encouraging initial pXRF results from its latest aircore drilling campaign targeting rare earth elements in South Australia's Mallee Project. Full assay results are pending, setting the stage for expanded exploration.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Knosys Limited reported a 4.6% revenue increase to $5.07 million for the half-year ending December 2025, driven by stronger licence and project fees. However, the company’s net loss widened significantly to $1.53 million, reflecting heavy investment in its next-generation Libero X library management system.

PathKey.AI Ltd has responded to ASX inquiries about a recent spike in its share price and trading volume, confirming no undisclosed information is driving the market activity. The company points to its recent strategic update and funding completion as context for investor interest.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Neometals Ltd has reported impressive new copper assay results from its historic Rinaldi workings within the Barrambie Gold Project, setting the stage for imminent drilling to explore this high-grade opportunity further.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Caterpillar has finalized its acquisition of RPMGlobal, paying shareholders A$5.00 per share and prompting RPMGlobal’s removal from the ASX. This marks a significant shift in the mining software landscape.

Judo Capital Holdings Limited has announced a quarterly distribution of AUD 1.825 per capital note, fully franked and payable on 18 May 2026. The payment reflects a calculated yield based on prevailing market rates and remains subject to company discretion.

Sports Entertainment Group reports a robust first half FY26 with nearly doubling EBITDA and declares special dividends following asset sales.

BKI Investment Company has finalised its on-market share purchases to satisfy its Dividend Reinvestment Plan obligations, setting the DRP price at $1.74 ahead of the 2026 interim dividend payment.